Novo Raises Forecast as Wegovy Pill Fuels Sales

Novo Nordisk reported better-than-expected Q1 earnings driven by Wegovy pill sales in the US, leading to a slight raise in full-year guidance. However, revenues and profit are still expected to decline for the year, and the company faces intense competition from Eli Lilly. The impact on the Danish economy remains a concern, but there is optimism given Novo's continued profitability and job creation. - Novo Nordisk reports Q1 earnings lifted by Wegovy pill sales in the US. - Company raises full-year guidance for adjusted sales and operating profit. - Operating margins came in at 62%, well above the 43% estimate. - Novo still expects revenue and profit to decline for the year. - Intense competition with Eli Lilly is a major challenge. - Novo is betting on lower prices and the Wegovy pill to regain market share. - The launch of the Wegovy pill in January is seen as encouraging. - Novo's fortunes have a significant impact on the Danish economy.